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Posttranslational arginylation mediated by arginyl-
transferase (ATE1) plays an important role in cardio-
vascular development, cell motility, and regulation of
cytoskeleton and metabolic enzymes. This protein
modification was discovered decades ago, however,
the arginylation reaction and the functioning of ATE1
remained poorly understood because of the lack of
good biochemical models. Here, we report the devel-
opment of an in vitro arginylation system, in which
ATE1 function and molecular requirements can
be tested using purified recombinant ATE1 isoforms
supplemented with a controlled number of compo-
nents. Our results show that arginylation reaction is
a self-sufficient, ATP-independent process that can
affect different sites in a polypeptide and that arginyl-
transferases form different molecular complexes
in vivo, associate with components of the translation
machinery, and have distinct, partially overlapping
subsets of substrates, suggesting that these
enzymes play different physiological functions.
INTRODUCTION
Arginylation is a poorly understood protein modification that
consists of posttranslational addition of arginine to proteins
(Kaji et al., 1963a, 1963b) and is mediated by arginyltransferase
(ATE1) (Balzi et al., 1990; Kwon et al., 1999; Rai and Kashina,
2005). Ate1 is an essential mouse gene, whose deletion causes
embryonic lethality and severe cardiovascular defects (Kwon
et al., 2002; Rai et al., 2008). It has been previously shown that
arginylation affects a large number of proteins (Kaji, 1976; Lamon
and Kaji, 1980; Soffer and Mendelsohn, 1966; Wang and Ingo-
glia, 1997; Wong et al., 2007; Xu et al., 1993) and that it regulates
in vivo functions of such essential proteins as actin (Karakozova
et al., 2006; Rai et al., 2008), regulators of G protein signaling
(RGS) (Lee et al., 2005), and calreticulin (Decca et al., 2007);
however, the underlying molecular mechanisms that driveChemistry & Biology 18, 121arginylation reaction and modulate ATE1 function are poorly
understood.
It has been previously hypothesized that arginylation in
mammals can occur only on the N-terminally exposed alpha
amino groups of Asp, Glu, and Cys and that such arginylation
targets proteins for degradation by the N-end rule pathway
that relates the half-life of a protein to the identity of its N-terminal
residue (Bachmair et al., 1986). Other groups have reported that
N-terminal Arg facilitates protein recognition by the ubiquitin
conjugation machinery (Elias and Ciechanover, 1990); however,
later studies suggested that not all protein substrates in vivo
undergo arginylation-dependent degradation and that the
relationship between arginylation and degradation may be
more complex (Karakozova et al., 2006; Wong et al., 2007). A
recent discovery that arginylation can occur in vivo on the acidic
side chain of glutamic acid (Eriste et al., 2005) makes it evident
that the arginylation mechanisms are even more complicated
than previously believed and opens up an exciting possibility
that arginylation can also occur on the side chain of other amino
acid residues.
Several past studies reported successful reconstitution of
arginylation reaction in vitro (Ciechanover et al., 1988; Kwon
et al., 2002; Soffer, 1970); however, these reactions have been
performed in crude cell extracts or partially purified preparations
without controlling for the arginyltransferase purity, making it
impossible to determine ATE1’s specificity and requirements
for cofactors or to fully address the mechanism of ATE1 action.
A discovery that mammalian Ate1 gene generates a subset of
highly homologous but distinct isoforms led to controversial
reports about these isoforms’ activities and substrate specific-
ities (Hu et al., 2006; Rai and Kashina, 2005; Rai et al., 2006),
further suggesting that the arginylation reaction in vivo may be
more complex than it appears. To add to the mystery, recent
identification of a large number of arginylated proteins in vivo
(Wong et al., 2007) raised a multitude of possibilities about the
arginylation reaction mechanisms and function. It was found
that, although arginylation affects unique sites on the surface
of the folded proteins, and thus is highly likely to constitute
a true regulatory modification, it has an apparently low specificity
for the primary sequence around the arginylation site, suggesting
that additional recognition cofactors may be required to direct
ATE1 to its appropriate protein targets. Arginylation frequently–130, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 121
Figure 1. Characterization of the Arginylation Reaction
(A) Time course of the incorporation of [3H]-Arg into BSA mediated by ATE1-2
(blue diamonds); control curves showarginylation reactionwith no addedATE1
(pink squares), no RRS (red triangles), and no BSA substrate (green crosses).
Inset shows aCoomassie-stained gel of ATE1-2 preparation used in the exper-
iments; ATE1-2 appears on the gel as a major band of approximately 60 kDa.
Curves were normalized to the last time point on the BSA arginylation curve,
taken as ‘‘1.’’ Numbers and error bars represent mean ± SEM (n = 3).
(B) Time course of [3H]-Arg into BSA from presynthesized [3H]-Arg-tRNA, per-
formed in the presence or absence of RRS (curves marked as + or – RRS,
respectively) or ATP (marked as + or – ATP). Curves were normalized to the
last time point on the –RRS- ATP curve, taken as ‘‘1.’’ Numbers and error
bars represent mean ± SEM (n = 5).
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as previously suggested, but also in the middle of the polypep-
tide chain, leading to a likely possibility that ATE1 might be
coupled with translation and/or proteolysis, by forming transient
or stable complexes with other proteins in vivo.
To resolve some of these questions and to develop a system
in which arginylation-related mechanisms can be tested directly,
we have expressed and purified functional mouse ATE1 iso-
forms and set up an in vitro system to analyze their activity,
requirement for cofactors, and potential relationship to other
posttranslational modifications, such as protein acetylation.
We have combined these studies with an in vivo analysis of
ATE1’s intracellular interactions that confirmed the earlier
hypotheses about the potential involvement of distinct functional
classes of proteins, including the components of the translation
machinery, in the in vivo arginylation reaction. Our results consti-
tute the first detailed analysis of the arginyltransferase function
in vitro and in vivo and demonstrate that ATE1 is a self-regu-
lating, ATP-independent enzyme forming distinct molecular
complexes in vivo that facilitate arginylation of multiple protein
substrates.
RESULTS
In Vitro Arginylation Assay
It has been previously established that arginylation reaction
occurs by ATE1-mediated transfer of Arg from the charged
tRNA to the protein substrate (Soffer, 1970), suggesting that
the minimal components for this reaction should include the
ATE1 enzyme, protein substrate, free Arg, tRNA, arginyl-tRNA
synthetase (RRS), and ATP (essential at least for the formation
of charged Arg-tRNA). It has also been found that bovine serum
albumin (BSA) can serve as an efficient substrate for ATE1,
because the removal of the signal peptide from the BSA’s N
terminus exposes the aspartic acid for the arginyl addition (Elias
and Ciechanover, 1990).We based our initial experiments on this
information. For the initial setup of the in vitro system for ATE1
activity assay, we expressed and purified His-tagged recombi-
nant mouse ATE1 isoforms from the Escherichia coli expression
system by Ni-NTA affinity chromatography and confirmed the
high yield, solubility, and purity of the resulting preparation
(Figure 1; see Figure S1A available online). A 70-kDa copurifying
band that could not be removed by either higher stringency
washes or by ion exchange chromatography was found in the
preparations of ATE1-3 or 1-4. Mass spectrometry identified
this band as bifunctional polymyxin resistance protein arnA
(NCBI accession number ARNA_ECOLI). Because no obvious
structural or functional connection could be found between
this protein and arginyltransferase, we assumed this to be
a nonspecific contaminant.
For the other components of the in vitro arginylation reaction,
we used bacterially expressed E. coli RRS (Figure S1), Arg-
specific tRNA from E. coli, [3H]-Arg, and nonacetylated BSA as
the substrate. The reaction was supplemented with ATP in the
presence of K+ and Mg2+.
Because it has been previously reported that out of the four
mouse ATE1 isoforms, ATE1-1 and ATE1-2 appear to have
higher activity and more universal substrate specificity (Rai and
Kashina, 2005; Rai et al., 2006), and ATE1-2 is the most ubiqui-122 Chemistry & Biology 18, 121–130, January 28, 2011 ª2011 Elsevtous ATE1 isoform in different mouse tissues (Rai and Kashina,
2005), we used ATE1-2 for the initial arginylation assay setup
and characterization of the arginyl transfer reaction. We found
that mixing purified ATE1-2 with BSA and the components
described above results in rapid and efficient incorporation of
[3H]-Arg into BSA (Figure 1A; Figures S1B and S1C). Control
experiments showed that although RRS used in this reaction
could efficiently catalyze the formation of [3H]-Arg-tRNA (Fig-
ure S1C), its activity without ATE1 present in the reaction did
not result in arginylation of the BSA substrate (Figure 1A; Figures
S1B and S1C). Therefore, mixing purified ATE1 with the protein
substrate and Arg-tRNA synthesis components results in a rapid
and efficient arginylation of the protein substrate.
To estimate the efficiency of arginylation reaction, we used the
estimation of the RRS activity shown in Figure S1 and found that
under these conditions approximately 10% of the synthesized
Arg-tRNA is consumed in the arginylation reaction at any given
moment of time in the linear range of the reaction.
Protein Arginylation Reaction Is RRS
and ATP Independent
It has been previously suggested (Ciechanover et al., 1988)
that, in addition to its role in synthesizing the chargedier Ltd All rights reserved
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ATE1 activity by forming a complex with ATE1 during the reac-
tion. It was also suggested that arginylation reaction is energy
dependent and that ATP hydrolysis is required for the ATE1-
mediated formation of protein-Arg bond. To test these two
hypotheses, we used a ‘‘two-step’’ arginylation assay, whereby
Arg-tRNA was first synthesized by RRS in the presence of ATP,
purified away from the protein, ATP, and buffer components,
and then used for in vitro arginylation by ATE1 in the presence
or absence of ATP. As seen in Figure 1B, no significant differ-
ence was detected between the arginylation reactions per-
formed in the absence and presence of RRS and/or ATP.
Control experiments using mass spectrometry and lumines-
cence ATP assays showed that no RRS or ATP detectable
by the assays was present in the purified Arg-tRNA prepara-
tions. Therefore, the arginylation reaction does not require
the formation of an ATE1-RRS complex or the presence
of ATP.
Arginyltransferase Is Able to Modify N-Terminal
and Internal Residues of a Protein Substrate
Among the biggest questions in recent arginylation studies have
been the discoveries that arginylation can happen on the amino
acid side chain (Eriste et al., 2005; Wong et al., 2007) and in
the middle of a protein (Wong et al., 2007), leaving open the
question of whether such Arg incorporation can be performed
by the same enzyme, and if so, whether it requires additional
cofactors in vivo. To address these questions and to identify
the sites for BSA arginylation in the in vitro reaction described
here, we performed arginylation as described above using
nonradioactive heavy isotope labeled [13C, 15N]-Arg and
subjected the resulting arginylated BSA protein to mass
spectrometry to detect the arginylated sites (Wong et al., 2007;
Xu et al., 2009). The results of this analysis (Figure S2 and Table
S2) showed that, although arginylation did happen with high
efficiency on the N-terminal Asp of BSA, additional internal
BSA sites were also arginylated, suggesting that in addition
to the N-terminally exposed residue arginyltransferase is also
able to transfer Arg to internal residues in a protein substrate.
Arginylation on two of these sites, Leu 139 and Cys 301 (Figures
S2C and S2D), likely occurs by ‘‘conventional’’ addition of Arg to
the N-terminally exposed alpha amino group and therefore must
involve additional preprocessing of the substrate protein,
possibly by partial proteolysis. Arginylation at Asp 135 (Fig-
ure S2B) could conceivably occur on the carboxy group of the
side chain of the aspartic acid, similar to the chemistry previously
described for the glutamic acid side chain (Eriste et al., 2005).
Proteolytic exposure of internal alpha amino groups in a protein
chain could happen either in vivo (e.g., by a previously proposed
mechanism of proteolytic processing of folded proteins that
could expose internal arginylation sites) (Wong et al., 2007) or
nonspecifically during the preparation and handling of commer-
cial BSA. The latter case is unlikely for Leu139, which was not
arginylated by the in vitro reaction, but was been found to be
pre-arginylated in the BSA preparation (as evidenced by the
addition of nonheavy stable isotope endogenous Arg rather
than Arg labeled with the heavy stable isotope) (Figure S2C),
suggesting that this site has been arginylated in vivo prior to
BSA isolation by the supplier.Chemistry & Biology 18, 121Four ATE1 Isoforms Have Different Activity In Vitro
Unlike lower organisms, the Ate1 gene in mammals encodes
a total of four ATE1 isoforms produced by different combinations
of four alternatively spliced exons (Kwon et al., 1999; Rai and
Kashina, 2005). Previous studies using yeast complementation
assays reported that two of these isoforms, ATE1-1 and
ATE1-2, are highly active on substrates containing N-terminal
Asp and Glu (Hu et al., 2006; Kwon et al., 1999; Rai and Kashina,
2005). Activity reports using this same assay, however, have
been controversial for ATE1-3 and ATE1-4, shown to be high
by one group (Hu et al., 2006), and low by the other with the
use of a different yeast expression system (Rai and Kashina,
2005; Rai et al., 2006). To resolve the controversy and charac-
terize the comparative activity of four ATE1 isoforms, we
performed a direct comparison of the in vitro arginylation activity
of these isoforms (Figure 2). Using BSA as a substrate, we found
that, although the activities of ATE1-1 and ATE1-2 were high and
relatively similar to each other, with ATE1-2 being slightly more
active (Figure 2A), the activity of ATE1-3 and ATE1-4 compared
to the other two isoforms appeared negligibly low or absent.
Plotting the activity of ATE1-3 and ATE1-4 on a smaller scale
compared to negative control (Figure 2B) showed that these
two isoforms appeared to have very weak activity with the BSA
substrate, amounting to 10% (ATE1-3) and 4% (ATE1-4) of the
activity of ATE1-1 in the same assay.
To test whether this difference in activity between the four
ATE1 isoforms is specific to BSA, we used a different substrate,
bovine alactalbumin, previously shown to be arginylated on the
N-terminal Glu (Elias and Ciechanover, 1990) (Figure 2C). In this
assay, four ATE1 isoforms exhibited a similar pattern to that with
BSA substrate: higher activity was detected with ATE1-1
and 1-2, and weaker activity was detected with 1-3 and 1-4.
Therefore ATE1-3 and ATE1-4 are indeed much less active
than ATE1-1/2 at least with some of the substrates containing
N-terminal Asp or Glu.
Four ATE1 Isoforms Have Distinct Substrate Specificity
The observed differences in activity between the four ATE1
isoforms suggest that ATE1-3 and ATE1-4may be less enzymat-
ically active than the other two isoforms. However, it has been
previously found that these two isoforms are as capable as
ATE1-1 and ATE1-2 of inducing the in vivo degradation of
RGS4, an N-end rule substrate containing N-terminal Cys (Davy-
dov and Varshavsky, 2000; Lee et al., 2005; Rai and Kashina,
2005), suggesting that at least in some cases these isoforms
may be as active as the other two. Therefore, it appears more
likely that ATE1-3/4 are in fact as active in vivo as ATE1-1/2,
but arginylate substrates different from BSA and a-lactalbumin
used in our in vitro assays. To test this possibility, we performed
the in vitro arginylation assay using Ate1/ cell extract as
a substrate, instead of BSA, and subjected the resulting mixture
toSDS-PAGE followedby autoradiography (Figure 3; FigureS3A)
to detect the gel positions of the proteins that incorporate
labeled Arg in the presence of each ATE1 isoform. One-dimen-
sional gel analysis showed that in the presence of cell extracts
all four ATE1 isoforms arginylated a large number of bands,
some of which were similar for different isoforms, including
a prominent 90-kDa band (Figure 3). Some other bands were
arginylated in the presence of only some but not other isoforms–130, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 123
Figure 3. Four ATE1 Isoforms Arginylate Distinct, Partially Overlap-
ping Pools of Substrates
Images of a Coomassie-stained gel (top) and autoradiograph (bottom) of
arginylation reactions using Ate1/ cell extracts as substrate (left five lanes)
or buffer as control (right four lanes). Numbers 1–4 represent ATE1 isoforms.
Middle lane had no ATE1 added, resulting in no incorporation of radioactive
Arg. See Figure S3A for 2D gel comparisons of samples similar to those
used in the left four lanes and Table S1 for the results of computerized compar-
ison of the gels. See Table 1 for the complete count of protein spots arginylated
by different ATE1 isoforms.
Figure 2. Four ATE1 Isoforms Have Different Activity Toward
Substrates Containing N-Terminal Asp or Glu
(A) Time course of [3H]-Arg incorporation into BSA in the presence of individual
ATE1 isoforms, and no-ATE1 control. Curves in all three panels were normal-
ized to the last time point on the ATE1-1 curve, taken as ‘‘1.’’ ATE1-1/2 have
much higher activity than ATE1-3/4. Numbers and error bars represent
mean ± SEM (n = 5).
(B) Three lower curves from (A) plotted on a different scale to show the activity
of ATE1-3 and 4. Numbers and error bars represent mean ± SEM (n = 5).
(C) Time course of [3H]-Arg incorporation into a-lactalbumin in the presence
of individual ATE1 isoforms, and no-ATE1 control. Differences in the ATE1
isoform activity are consistent for different substrates. Numbers and error
bars represent mean ± SEM (n = 3).
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ATE1-3-arginylated extracts; Figure 3). To resolve this further
and estimate the numbers of overlapping and isoform-specific
ATE1 substrates, we subjected arginylated proteins from each
reaction mixture to 2D gel electrophoresis followed by autoradi-
ography. Computerized comparison of the positions of the
arginylated protein spots on each of the four gels corresponding
to individual ATE1 isoforms (Table 1; Figure S3Aand Table S1)
showed that among the total of 144 protein spots found to be
arginylated under these conditions, themajority (59) were shared124 Chemistry & Biology 18, 121–130, January 28, 2011 ª2011 Elsevbetween all four ATE1 isoforms, and the remaining arginylated
spots were either isoform specific or were shared between
some but not other ATE1 isoforms. The ATE1 isoform arginylat-
ing the largest number of protein spots was ATE1-2 (108 protein
spots on 2D gels); this isoform was also previously found to
be the most ubiquitously expressed in different mouse tissues
(Rai and Kashina, 2005) and apparently the most active one
in the in vitro assays (Figure 2). The other three isoforms
arginylated 74, 92, and 90 protein spots (seen on 2D gels with
ATE1-1, 3, and 4, respectively; see also Table 1 for the spot
number breakdown). These results suggest that, despite the
observed differences in vitro and in yeast complementation
assays using protein substrates with N-terminally exposed Asp
and Glu, all four ATE1 isoforms likely have high activity in vivo
and arginylate partially overlapping but distinct subsets of
substrates.
Differential Activity of ATE1 Isoforms Is Defined
by Cofactors from the Cell Extracts
Although the experiments described above suggest that
ATE1-3/4 may be as active as the other two ATE1 isoforms
with a certain subset of substrates, it is still unclear whether their
inability to efficiently arginylate BSA and a-lactalbumin in vitro
reflects the situation in vivo. It has been previously suggested
that ATE1 enzymes by themselves have low specificity for the
arginylation sites, and their specificity in vivo is determined by
other cofactors bound to these enzymes (Wong et al., 2007).
To test whether endogenous protein or nonprotein factors
could aid ATE1-3/4, we performed the in vitro a-lactalbumin
arginylation assay in the presence of Ate1/ cell extractsier Ltd All rights reserved
Table 1. Number of Protein Spots Arginylated in Cell Extracts by
Different ATE1 Isoforms
Isoform No. of Spots
ATE1-1 2
ATE1-2 39
ATE1-3 11
ATE1-4 6
ATE1-1/2 2
ATE1-1/4 2
ATE1-2/4 1
ATE1-3/4 6
ATE1-2/3/4 7
ATE1-1/3/4 9
ATE1-1/2/3/4 59
Total 144
Figure 4. ATE1-3 andATE1-4 Are Partially Aided by Factors fromCell
Extracts in Arginylating a-Lactalbumin
Top, autoradiographs of the gels on the bottom, showing incorporation of
[14C]-Arg into a-lactalbumin by each of the ATE1 isoforms (labeled 1–4 on
top) in the presence (left) or absence (right) of the added cell extract. Control
lane shows arginylation reaction without the addition of ATE1. Consistent
with the results of the scintillation counting (Figure 2), ATE1-3/4 have much
weaker activity toward a-lactalbumin than ATE1-1/2. Addition of cell extracts
enhances the ability of ATE1-3/4 to arginylate a-lactalbumin. See also
Figure S4.
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in the absence and presence of the extracts by autoradiography.
Although, consistent with the assays shown in Figure 2,
ATE1-3/4 in the absence of cell extracts showed very poor ability
to arginylate a-lactalbumin (Figure 4, right), the activity of these
two isoforms in the presence of cell extracts appeared to
increase (Figure 4, left), suggesting that added cell extract
does have an effect on the ability of ATE1-3/4 to arginylate
a-lactalbumin. The addition of increasing doses of cell extract
to the reaction mixture (Figure S4) showed that at lower concen-
trations Ate1/ extract was indeed able to ‘‘rescue’’ the activity
of ATE1-3/4 toward a-lactalbumin; however, the increase of the
extract-to-substrate ratio negated this effect, possibly because
of the competition between a-lactalbumin and the endogenous
substrates found in the cell extract. These experiments suggest
that additional cofactors in the cell extract are needed to
increase the activity of ATE1 isoforms toward unfavorable
substrates, either via direct interaction or via additional level of
posttranslational regulation, supporting the hypothesis that
substrate recognition and/or catalysis by ATE1 in some cases
is aided by other proteins in vivo.
ATE1 Is Capable of Self-Arginylation
During the autoradiography to detect the activity of individual
ATE1 isoforms in the presence of cell extracts (Figure 3),
in vitro arginylation reactions without the added extracts were
used as a control (right lanes on the gel and autoradiograph in
Figure 3). Remarkably, significant Arg incorporation into the
ATE1 gel bands was detected in these experiments, suggesting
that in the absence of other substrates, ATE1 isoforms undergo
self-arginylation. Arginylated protein bands corresponding to
ATE1 molecular weight were also detected in cell extracts
(Figure 3, left lanes), suggesting that self-arginylating activity of
ATE1 isoforms is independent of the presence of other
substrates and cell extract–specific cofactors. In addition to
the full-length ATE1 (60 kDa), minor 50-kDa and 40-kDa bands
were also significantly arginylated in purified ATE1 preparations;
control immunoblots with ATE1 antibody suggest that these
bands may represent truncated ATE1 fragments, because minor
bands corresponding to these ATE1 fragments were present in
the His-tag-purified ATE1 preparation (Figure S3B).Chemistry & Biology 18, 121To test whether ATE1 can indeed undergo self-arginylation,
we performed a separate arginylation assay using purified
ATE1 isoforms without added substrates, and [13C, 15N] heavy
isotope–labeled Arg for the transfer reaction, and analyzed
ATE1 isoforms in the reaction mixture by mass spectrometry to
detect the arginylated sites (Figure 5; Figure S5 and Table S2).
This assay revealed several heavy isotope–labeled arginylation
sites in each isoform, located on the N terminus and internal
amino acid residues (as marked in Figure 5). In addition to the
heavy isotope–labeled sites, a number of sites, especially in
ATE1-3/4, were labeled by ‘‘light’’ Arg, indicating that arginyla-
tion on these sites happened during ATE1 expression in E. coli.
Some sites (A2, S3, D117/D110, S251/S244, and N485/N478)
were conserved between two or more isoforms, and others
(Y54 and G411) appeared to be ATE1-4 specific. Their identity
may partially underlie the different activity of ATE1 isoforms.
Although method limitations precluded us from accurately
determining the stoichiometry of arginylation, a crude estimation
by the number of detected peptides in isoforms ATE1-1/2
suggested that arginylation was the most abundant on residues
2 and 3 from the N terminus. Similar sites in both isoforms were
also found acetylated, suggesting that arginylation and acetyla-
tion may both be involved in this previously unknown N-terminal
processing of ATE1. This result suggests that ATE1 enzymes
undergo self-arginylation, a process that may be essential for
their in vivo function.ATE1 Forms Different Functional Complexes In Vivo
To gain insights into the molecular interactions of ATE1 isoforms
in vivo, we fractionated crude cell extracts on a wide-range
sucrose density gradient (0%–70%) and analyzed the ATE1
distribution between different intracellular fractions (Figure 6a;
Figure S6A). Under these conditions, ATE1 sedimented as two
peaks, one at the top of the gradient corresponding to the–130, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 125
Figure 5. ATE1 Is Capable of Self-Arginylation
In Vitro and In Vivo
Top, schematic representation of Ate1 gene, with the
alternatively spliced exons shaded in dark and light gray.
Bottom, exon maps of four ATE1 isoforms, showing the
location of the arginylated sites. For each site, red star
indicates arginylation, letters and numbers represent
amino acid residue and its position within the polylpeptide.
Blue stars represent the sites that can also undergo acet-
ylation. See Figure S5 for the arginylated peptide mass
spectra and Table S2 for the peptide parameters.
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corresponding to the midsize cytoplasmic organelles (smaller
than mitochondria and larger than soluble protein oligomers).
Probing the same fractions with different intracellular markers
suggested that ATE1 fully colocalized with the elongation factor
eEF1B2 (a component of the translation machinery), and its
higher density peak colocalized with the microsomal fraction
probed by the endoplasmic reticulum maker cytochrome P450
oxidoreductase (CYPOR). In addition, colocalization of ATE1
with the ribosomal protein L7a was also observed in most
fractions, excluding the nucleus and the mitochondria. No
significant colocalization of ATE1 with mitochondria (probed by
anti–cytochrome C oxidase, COX IV) was observed. Despite its
demonstrated ability to modify actin cytoskeleton, ATE1 was
not associated with the major pool of actin filaments (found in
the bottom fractions cofractionating with the mitochondria and
the nuclei); however, it partially colocalized with the tubulin/
microtubule pool. Fractionation of only the soluble ATE1 peak
(high-speed supernatant fraction of the cell lysate) (Figure S6B)
confirmed the colocalization of ATE1 with eEF1B2, and the
absence of stable association with the tubulin pool. Thus,
ATE1 in vivo exists in two different pools that likely reflect its
involvement in two molecular complexes, one soluble and
one at least partially associated with the translation machinery,
ribosomes, and the endoplasmic reticulum.
To further test whether ATE1 can associate with the ribo-
somes, we performed cosedimentation assays between ATE1
from mouse liver cell extracts and the ribosomes from rabbit
reticulocyte lysates (RRL) (Figure 6B). Although a small amount
of ATE1 sedimented through the sucrose cushion in the absence
of the ribosomes (Figure 6B, left lanes), suggesting this enzyme’s
ability to aggregate, a much larger fraction of ATE1 was found
when it was pelleted in the presence of the ribosomes (Figure 6B,
right lanes), indicating its ability to bind to the ribosomes in
this assay. We also used ATE1 antibody to study the intracellular
localization of ATE1 protein in cultured mouse embryonic
fibroblasts (Figure 6C). It has been previously found that
overexpressed ATE1-GFP fusion proteins localize in distinct
intracellular patterns, diffuse in the cytoplasm with or without
enrichment at the cell leading edge, and in some cases highly
concentrated in the nucleus (Kwon et al., 1999; Rai and Kashina,
2005). Consistent with these observations, ATE1 in mouse126 Chemistry & Biology 18, 121–130, January 28, 2011 ª2011 Elsevier Ltd All rights rembryonic fibroblasts localized diffusely, with
prominent enrichment at the leading edge
(arrows in the left two panels in Figure 6C)
and, in some cases, in the nucleus (arrow inthe rightmost panel in Figure 6C). ATE1 in the cytoplasm local-
ized in distinct dots, which partially overlapped with the dots
stained by anti-eEF1B2 (Figure 6D), confirming the results of
the sucrose gradient fractionation and suggesting that ATE1 in
cells partially associates with the ribosomes and the translation
machinery in addition to its ribosome-independent localization
in the cytoplasmic pool.
DISCUSSION
The results described above constitute the first detailed study of
arginyltransferase in vitro and in vivo, providing insights into the
complexity of protein arginylation and some of the mechanisms
that ensure efficient ATE1-dependent protein regulation. Our
data show that ATE1 requires nothing else but a charged
Arg-tRNA and a protein substrate to conduct the reaction, and
that this enzyme undergoes self-arginylation in vitro and
in vivo, which may constitute a previously unknown step in the
regulation of its activity and in vivo function. Our data also
demonstrate that different ATE1 isoforms can arginylate distinct,
partially overlapping subsets of substrates, suggesting that
these isoforms perform different functions in vivo, and that
ATE1 enzymes are aided by in vivo cofactors and form distinct
molecular complexes associated with different subcellular
structures.
It has been previously found (Eriste et al., 2005; Wong et al.,
2007) that posttranslational addition of Arg can happen not
only on the N-terminally exposed amino acid residue, but also
on the internal residues, presumably via a novel chemistry that
couples Arg amino group to the carboxyl groups of the side
chains of Asp and Glu (Eriste et al., 2005). Our data with
in vitro arginylation of the internal Asp in BSA suggest that this
reaction may be mediated by ATE1 itself, without additional
cofactors or enzymes, suggesting that ATE1 can employ
different mechanisms for Arg addition and that arginylation on
the side chains of acidic residues seen in vivo may also be also
conducted by the same enzyme.
Previous characterization of ATE1 isoforms resulted in contro-
versial reports, where two independent groups showed that
ATE1-3 and ATE1-4 can have different activity toward the
same substrates in different experimental systems (Hu et al.,
2006; Rai and Kashina, 2005; Rai et al., 2006). Our data, showingeserved
Figure 6. ATE1 in Cells Forms Pools that Colocalize with Different
Intracellular Fractions
(A) 0%–70% sucrose gradient fractions of the whole cell lysate probed with
antibodies to different intracellular markers, including ATE1, component of
the translation machinery eEF1B2, ribosomal protein L7a, microsomal/ER
marker CYPOR, mitochondrial marker COX IV, and cytoskeletal markers actin
and tubulin. ATE1 localizes in two distinct pools, one soluble and one associ-
ated with ER and the translation machinery.
(B) Cosedimentation of ATE1 from mouse liver extracts with the ribosomes
from rabbit reticulocyte lysates (RRL). Substantial amounts of ATE1 are found
in the pellets in the presence but not the absence of the ribosomes.
(C) Intracellular localization of ATE1 using rat monoclonal anti-ATE1 recog-
nizing all four isoforms shows distinct localization patterns in the nucleus
and cytoplasm, with enrichment at the cell leading edge (arrows in middle
and left image) and in the nucleus (arrows in right image).
(D) ATE1 in the cytoplasm forms dots and punctate patterns that partially
colocalize with eEF1B2 (arrows in right image show colocalization of ATE1
[red] and eEF1B2 [green]).
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Figure 7. Model of ATE1 Molecular Interactions
ATE1 enzyme forms two different cytoplasmic pools, one cytosolic and one
ribosome-bound, and can arginylate protein N termini and side chains. Its
association with ribosomal proteins facilitates cotranslational arginylation,
allowing ATE1 to effectively compete with acetylation and to modify proteins
in the most efficient way.
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substrates in vitro but are apparently aided by intracellular cofac-
tors to achieve efficient Arg transfer onto the same substrates in
cell extracts, resolve this controversy, suggesting that the
discrepancies observed by the two groups are due most likely
to the action of specific cofactors found in different experimental
systems.
It has been previously suggested (Ciechanover et al., 1988)
that ATE1 forms a hexamer containing three molecules of
ATE1 and three molecules of RRS, and that the formation of
this complex is required for ATE1’s function. Our data, however,
suggest that RRS is not a required component of arginyl transfer
reaction.Chemistry & Biology 18, 121Our finding that ATE1 can undergo self-arginylation in vitro and
in vivo suggests that this enzyme may self-regulate its activity in
application to its diverse biological functions. Our in vitro Arg
incorporation data (Figure 1A) suggest that the levels of ATE1
self-arginylation are negligibly low, indistinguishable from the
background. These data may reflect the low level of self-arginy-
lation in vivo. An alternative intriguing possibility, however, is that
ATE1 self-arginylation levels are actually high, but that the
majority of it happens during its expression in E. coli, blocking
the arginylation sites that could have otherwise been utilized in
the in vitro reaction. In support of this, we find that some ATE1
sites are modified by ‘‘light’’ Arg and not the heavy isotope–
labeled Arg derivative used in our in vitro reaction. Overall, the
question of the abundance and the exact role of ATE1 self-argi-
nylation is an intriguing subject for further investigation.
On the basis of our results, we propose a model of ATE1
molecular interactions (Figure 7). Although a small portion of
ATE1 under certain conditions localizes to the nucleus (data
not shown), a prominent subset of ATE1 is found in the soluble,
cytosolic fraction, where it presumably forms complexes with
different cofactors. Another subset is associated with ribosomes
and/or ER. Although this pool of ATE1 can form complexes with
the same proteins and cofactors, it is possible that its intracel-
lular role includes cotranslational arginylation of proteins on the
ribosomes, accounting for the arginylation on the internal sites
of the polypeptides and the side chains of certain amino acid
residues. Finally, under some physiological conditions, a subset
of ATE1 localizes in the nucleus, where it may mediate arginyla-
tion of specific nuclear proteins. The biological role of these
different ATE1 pools and the identity of arginylated proteins
constitute an exciting direction of further study.SIGNIFICANCE
Our study reports the first, to our knowledge, characteriza-
tion of arginyltransferase using in vitro arginylation reaction,
following nearly 40 years of attempts to determine which
factors are essential to conduct this enigmatic protein–130, January 28, 2011 ª2011 Elsevier Ltd All rights reserved 127
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that arginylation requires no additional factors besides the
ATE1 enzyme, the charged Arg-tRNA, and the protein
substrate. We also found that ATE1 can transfer Arg not
only to the N terminus, but also to the internal sites in
a protein substrate, and that it is capable of self-arginylation,
which is likely involved in its in vivo regulation. Our system
enabled us to address a recent controversy about the differ-
ences in mammalian ATE1 isoforms and show that these
isoforms have partially overlapping but distinct subsets of
substrates and that they are aided by intracellular cofactors
that facilitate their functions. Finally, we found that ATE1 can
form different in vivo complexes and associate with the
components of the translation machinery. These data
constitute the first mechanistic insights into the arginylation
reaction and are an essential first step that would enable
further studies to understand the molecular components
and mechanisms involved in this poorly understood post-
translational modification.
EXPERIMENTAL PROCEDURES
Cells and E. coli Strains
For immunostaining and cell extract preparation, immortalized mouse
embryonic fibroblasts derived from wild-type and Ate1/ mouse embryos
were used, as described elsewhere (Karakozova et al., 2006). For protein
expression, BL21-CodonPlus (DE3)-RIL and BL21(DE3) were purchased
from Stratagene (USA).
Expression and Purification of the Recombinant Mouse
ATE1 Isoforms and E. coli Arg-tRNA Synthetase
cDNAs encoding mouse ATE1 isoforms (Rai and Kashina, 2005) were
subcloned into pET29a (Novagen) containing C-terminal His6 tag followed
by TEV cleavage site. ATE1 isoforms were expressed in BL21-CodonPlus
(DE3)-RIL E. coli strain using LB medium supplemented with 50 mg/ml
kanamycin at 37C. When the optical density (OD 600nm) of the bacterial
culture reached 0.4–0.5, the culture was cold shocked on ice for 30 min, and
then induced with 0.8 mM IPTG (isopropyl-1-thiod-galactopyranoside) for
18 hr at 16C. For ATE1 purification, cells were collected by centrifuging at
6000 rpm for 30 min; were resuspended in lysis buffer (50 mM Tris, 5 mM
imidazole [pH7.5]) containing 0.5 M NaCl, 1 mM MgCl2, 10 mM b-mercaptoe-
thanol, and 1 mM PMSF; and were lysed using a French press at 4C. The
lysate was centrifuged at 20,000 rpm for 30 min, and the supernatant was
loaded to the Ni-NTA agarose column (QIAGEN) equilibrated with the lysis
buffer, followed bywashing in 50mMTris, 25mM imidazole (pH 7.5) containing
1 M NaCl, 1 mM MgCl2, and 10 mM b-mercaptoethanol. Protein was
eluted with 50 mM Tris and 0.5 M imidazole (pH 7.5) containing 0.5 M NaCl,
1 mM MgCl2, and 10 mM b-mercaptoethanol, and was dialyzed against
50 mM HEPES (pH 7.5) containing 2 mM DTT, 1 M NaCl, 0.2 mM EDTA, and
2 mMMgCl2 overnight at 4
C. E. coli arginyl-tRNA synthetase was subcloned
into pTYB1 (New England Biolabs) and was expressed in BL21(DE3) in LB
supplemented with 100 mg/ml ampicillin at 37C, followed by induction with
0.5 mM IPTG for 16 hr at 37C. Cells were collected by centrifugation at
6000 rpm for 30 min and were resuspended in lysis buffer (0.5 M NaCl,
20 mM Tris, 1 mM EDTA, 0.1% Triton X100, and 1 mM PMSF [pH 8.5]),
followed by lysis using a French press at 4C. Cell lysates were clarified by
centrifugation at 20,000 rpm for 30 min and loaded onto a chitin column
(New England Biolabs) equilibrated with the lysis buffer. The column was
quickly flushedwith lysis buffer containing 30mMDTT and left at 4Covernight
for on-column cleavage. Protein was eluted using 3 column volumes of lysis
buffer without DTT. Final preparations of ATE1-1, 2, 3, and 4 were mixed
with equal volume of glycerol and kept at 80C. Dialysis and storage of
purified E. coli RRS were the same as ATE1. The estimated purity of each
purification product was >90%; about 5 mg of ATE1 isoforms or 2 mg of
RRS was obtained per liter of LB, respectively.128 Chemistry & Biology 18, 121–130, January 28, 2011 ª2011 ElsevAssay of ATE1 Activity
In vitro assay of ATE1was derived andmodified fromCiechanover et al. (1988).
L-[2,3-3H]-Arginine (Sigma; 40 Ci/mmol), L-[2,3,4,5-3H]-Arginine (GE
Healthcare; 54 Ci/mmol), L-[14C(U)]-Arginine (Moravek Biochemicals; 310
mCi/mmol), and L-[13C,15N]-Arginine (Pierce) dissolved in water to 100 mM
were used throughout the project. A typical reaction was performed in 50 ml
volume, containing 50 mM HEPES (pH 7.5), 25 mM KCl, 15 mM MgCl2,
0.1 mM DTT, 2.5 mM ATP, 12.5 uM [3H]-Arginine, 40 mM tRNAArg, 2 mg RRS,
1 mg ATE1, and 8.3 mM BSA as a substrate. Reaction was mixed and kept on
ice for 0 min time point, then started by placing into a heat block at 37C,
and a 10-ml aliquot was taken out at each time point (usually at 0, 10, 20, 30,
and 40 min). For scintillation counting, samples at each time point were
immediately quenched into 40 ml of 20% trichloroacetic acid (TCA) containing
1 mM of unlabeled Arg and kept at room temperature for at least 10 min, fol-
lowed by heating at 95C for 15 min (to destroy the excess of the labeled
Arg-tRNA), cooling down on ice for 20 min, and spinning at 13,000 rpm for
30 min at room temperature to collect the pellets containing precipitated
proteins. Pellets were washed three times with 5% cold TCA and once with
cold acetone, air-dried, and counted in a liquid scintillation counter. Control
reactions excluding ATE1, RRS, or BSA, plus a control reaction for RRS activity
(no ATE1, no heating) were used as indicated in the figures. ATE1 activity was
evaluated as counts per minute (cpm) of [3H]-Arg at each time point. For auto-
radiography, [14C]-Arg instead of [3H]-Arg was used in the reaction. Samples at
each data point were mixed 1:1 with 23 SDS sample buffer and boiled. For
mass spectrometry, [13C,15N]-Arg was used in the reaction. Samples after
40min of arginylationwere TCAprecipitated and processed as described else-
where (Wong et al., 2007; Xu et al., 2009). Different substrates, including non-
acetylated BSA, a-lactalbumin (Sigma), orAte1/ cell extract (prepared by the
lysis of Ate1/ fibroblasts followed by centrifugation at 67,917 g and addition
of 100 mg/ml of cycloheximide to block the potential translation) were used as
indicated in the text and figures. For RRS and ATP-independent assays shown
in Figure 1B, the arginylation reaction was performed in two steps. First, [3H]-
Arg wasmixed with all the reaction components except ATE1 and incubated at
37C for 60min for RRS-mediated coupling to tRNA. Then 0.2 U/ml hexokinase
and glucose-6-phosphate dehydrogenase (Sigma),10 mM glucose, and
10 mM b-nicotinamide adenine dinucleotide phosphate (Sigma) were added
to the reaction and incubated at 37C for 30min to deplete the ATP. The result-
ing [3H]-Arg-tRNA was extracted three times with chloroform and further puri-
fied with RNesay Mini Kit(QIAGEN) with slight modifications: 700 ml 100%
ethanol was added to each 100 ml of Arg-tRNA solution, and 350 ml of buffer
RLT mixture was used instead of the 250 ml recommended by the manufac-
turer. A 1/10 volume of [3H]-Arg-tRNAwas taken for liquid scintillation counting
tomonitor the efficiency of the RRS reaction. The absence of the RRS and ATP
contamination in the final preparation was confirmed by mass spectrometry
and FLAAM ATP assay detection kit (Sigma) using Luminoskan Ascent
(Thermo Scientific), respectively. As the second step of the reaction, the puri-
fied [3H]-Arg-tRNA was used as donor for the ATE in vitro assay.
2D Gel Electrophoresis and Comparison
Two-dimensional electrophoresis was performed according to the carrier
ampholine method (O’Farrell, 1975) by Kendrick Labs, Inc. (Madison, WI) as
described in the Supplemental Experimental Procedures.
Computerized Comparisons
Films from each sample were scanned with a laser densitometer (Model PDSI,
Molecular Dynamics Inc, Sunnyvale, CA). The scanner was checked for line-
arity prior to scanning with a calibrated Neutral Density Filter Set (Melles Griot,
Irvine, CA). The images were analyzed using Progenesis Same Spots software
(version 3.2, Nonlinear Dynamics) and Progenesis PG240 software (version
2006), Nonlinear Dynamics. The general method of computerized analysis
for each included image warping followed by spot finding, background
subtraction (average on boundary), matching, and quantification in conjunc-
tion with detailed manual checking. Spot percentage equal to spot integrated
density above background (volume) was expressed as a percentage of total
density above background of all spots measured. Difference was defined as
fold-change of spot percentages.
Molecular Weight and pI Measurements
Approximate isoelectric point (pI) measurements were made based on the
pH gradient plot included with the gels for this batch of ampholines forier Ltd All rights reserved
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and pI values for each spot were determined from algorithms applied to the
reference image.Sucrose Gradient Fractionation of Cell Lysates
Livers from wild-type mice were removed immediately following euthanasia,
washed with ice-cold lysis buffer (100 mM KCl and 50 mM Tris [pH 7.0]),
minced with scissors, mixed with 1:1 (w/v) lysis buffer supplemented with
20 mM mammalian Protease Inhibitor Cocktail (Sigma), and homogenized in
a Potter-Elvehjem homogenizer with a motor-driven Teflon pestle using 6–8
strokes at 2,500 rpm. Liver homogenates were filtered through four layers of
cheese cloth. For whole-cell fractionation, filtered homogenates were loaded
onto 0%–70% linear sucrose gradient in lysis buffer with protease inhibitors,
and centrifuged at 77,175 g for 1.5 hr at 4C using SW 41 Ti rotor (Beckman).
After centrifugation, 400 ml of each fraction was collected from the top, and
a 10-ml aliquot from each fraction was taken for gel analysis. For analysis of
the soluble ATE1 pool, filtered homogenates were centrifuged sequentially
at 1,500, 16,000, and 67,917 g at 4C for 30 min. At each step, gel samples
of supernatant and resuspended pellet were collected for SDS PAGE. Super-
natant from the last centrifugation step (500 ml) was loaded onto 5%–20%
linear sucrose gradient in lysis buffer with protease inhibitors, and centrifuged
at 84,168 g for 14 hr at 4C using SW 50.1 rotor (Beckman). After centrifuga-
tion, 250-ml fractions were collected from the top and a 10-ml aliquot from
each fraction was taken for SDS PAGE. Fractions from both gradients were
analyzed by western blots using rat monoclonal anti-ATE1 antibodies raised
by Absea, Inc. against purified His6-tagged mixture of ATE1-1 and ATE1-2
that recognize all four ATE1 isoforms (Kurosaka et al., 2010); rabbit polyclonal
antibodies to eEF1B2 (Abcam); rabbit polyclonal antibodies to the Ribosomal
Protein L7a (Cell Signaling Technology); anti-actin (Cytoskeleton, Inc.); mouse
anti-b-Tubulin (Sigma); mouse anti–cytochrome c oxidase subunit 4 isoform
(COX IV) (Mitosciences); mouse anti–cytochrome P450 oxidoreductase
(CYPOR) (Santa Cruz Biotechnology); and mouse anti–dynein intermediate
chain (DIC) (Fisher Scientific). Western blot quantifications were performed
using ImageQuant TL (GE Healthcare).
Ribosome cosedimentation assays were performed by ultracentrifugation
as described in the Supplemental Experimental Procedures. Mass spectrom-
etry and database searches were previously described (Wong et al., 2007;
Xu et al., 2009). See Supplemental Experimental Procedures for the detailed
description.SUPPLEMENTAL INFORMATION
Supplemental Information includes two tables, six figures, and Supplemental
Experimental Procedures and can be found with this article online at doi:10.
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